Literature DB >> 12462387

Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma.

Yasuhiro Ito1, Hisaaki Kawakatsu, Tsutomu Takeda, Naoyuki Tani, Naomasa Kawaguchi, Shinzaburo Noguchi, Takao Sakai, Nariaki Matsuura.   

Abstract

In order to investigate whether c-Src is involved in carcinogenesis and progression of breast carcinoma, we examined the expression of activated c-Src in tissue sections from surgically resected human breast specimens. First, we confirmed the specificity of the antibody against activated c-Src (Clone 28) using six cell lines established from human breast carcinomas by western blotting. As expected, activated c-Src was detected as a 60 kDa band in all cell lines tested. Immunofluorescence analysis demonstrated that the activated c-Src was mainly observed in cytoplasms of these cells. Then, we designed an immunohistochemical study with 73 human breast carcinoma tissues. Glandular epithelial and myoepithelial cells in normal mammary glands adjacent to carcinoma nests and infiltrating stromal cells were negative for activated c-Src. In contrast, 37 of the 73 breast carcinoma tested (50.7%) were positive for activated c-Src, and this positive staining was inversely correlated with Ki-67 labeling index (p < 0.0001), TNM stage (p < 0.0001), tumor size (p < 0.0001), an d histological grade (p = 0.0002). These results strongly suggest that the activation of c-Src would be related to the progression of breast carcinomas with low aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462387     DOI: 10.1023/a:1020860221099

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Fertilization triggers localized activation of Src-family protein kinases in the zebrafish egg.

Authors:  Dipika Sharma; William H Kinsey
Journal:  Dev Biol       Date:  2006-04-04       Impact factor: 3.582

2.  Localized activation of Src-family protein kinases in the mouse egg.

Authors:  Lynda K McGinnis; David F Albertini; William H Kinsey
Journal:  Dev Biol       Date:  2007-03-24       Impact factor: 3.582

3.  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

Authors:  Ayca Gucalp; Joseph A Sparano; James Caravelli; Jean Santamauro; Sujata Patil; Alyson Abbruzzi; Christine Pellegrino; Jackie Bromberg; Chau Dang; Maria Theodoulou; Joan Massague; Larry Norton; Clifford Hudis; Tiffany A Traina
Journal:  Clin Breast Cancer       Date:  2011-05-03       Impact factor: 3.225

Review 4.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

5.  Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.

Authors:  Christina Michailidi; Costas Giaginis; Vassilios Stolakis; Paraskevi Alexandrou; Jerzy Klijanienko; Ioanna Delladetsima; Nicolaos Chatzizacharias; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2010-04-20       Impact factor: 3.201

6.  Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?

Authors:  Beatrix Elsberger; Bingchao A Tan; Thomas J Mitchell; Sylvia B F Brown; Elizabeth A Mallon; Sian M Tovey; Timothy G Cooke; Valerie G Brunton; Joanne Edwards
Journal:  Am J Pathol       Date:  2009-09-17       Impact factor: 4.307

7.  Naphtho[1,2-b]furan-4,5-dione inhibits MDA-MB-231 cell migration and invasion by suppressing Src-mediated signaling pathways.

Authors:  Pei-Chien Tsai; Chiao-Lun Chu; Yaw-Syan Fu; Chih-Hua Tseng; Yeh-Long Chen; Long-Sen Chang; Shinne-Ren Lin
Journal:  Mol Cell Biochem       Date:  2013-10-26       Impact factor: 3.396

8.  Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival.

Authors:  B Elsberger; B A Tan; E A Mallon; V G Brunton; J Edwards
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

9.  Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.

Authors:  G R Wilson; A Cramer; A Welman; F Knox; R Swindell; H Kawakatsu; R B Clarke; C Dive; N J Bundred
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

10.  Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

Authors:  E J Campbell; E McDuff; O Tatarov; S Tovey; V Brunton; T G Cooke; J Edwards
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.